neutral
antibodi
provid
one
arm
adapt
immun
respons
human
immunodefici
viru
type
sever
report
demonstr
neutral
antibodi
respons
exert
select
pressur
replic
vivo
account
part
extens
variat
env
gene
observ
soon
primari
infect
furthermor
select
pressur
impos
neutral
antibodi
demonstr
human
trial
three
neutral
monoclon
antibodi
mab
administ
haart
treatmentinterrupt
led
reduct
viremia
follow
select
escap
mutant
passiv
transfer
studi
macaqu
show
administr
neutral
mab
protect
vagin
intraven
challeng
chimer
virus
shiv
model
protect
depend
viral
neutral
also
fcmediat
antibodi
effector
function
given
predict
lowtit
inoculum
drive
sexual
transmiss
vaccin
capabl
elicit
antibodi
neutral
broad
spectrum
viral
strain
could
potenti
reduc
prevent
infect
anticip
identif
broadli
neutral
mab
infect
individu
character
cognat
epitop
instrument
design
immunogen
capabl
elicit
broad
neutral
respons
idea
led
major
intern
cooper
effort
within
consortia
laboratori
complementari
expertis
human
immunolog
structur
biolog
vaccin
design
character
extraordinari
genet
divers
reflect
presenc
sever
clade
subtyp
fact
repres
signific
impedi
vaccin
develop
env
variabl
gene
sequenc
divers
among
clade
divers
within
clade
divers
singl
infect
individu
sever
conserv
epitop
defin
small
panel
neutral
mab
isol
use
differ
experiment
approach
one
epitop
appear
rel
conserv
overlap
bind
site
surfac
env
glycoprotein
recogn
mab
potent
broadlyreact
mab
specif
site
recent
shown
signific
target
neutral
antibodi
present
sera
select
patient
howev
deriv
phage
librari
heavi
light
chain
randomli
reassort
thu
relev
naturallyoccur
b
cell
respons
infect
unclear
second
epitop
carbohydraterich
region
outer
domain
compos
glycan
recogn
mab
show
unusu
interlock
vh
domainswap
dimer
gener
extend
monoval
bind
surfac
epitop
present
major
clade
c
isol
concern
activ
detect
sera
infect
individu
suggest
type
neutral
antibodi
may
gener
amen
elicit
b
cell
third
target
broadlyneutr
mab
rel
broad
mab
locat
membraneproxim
extern
region
mper
transmembran
glycoprotein
mperspecif
neutral
antibodi
infrequ
encount
sera
individu
potenti
reduc
relev
vaccin
develop
strategi
moreov
mperspecif
mab
featur
suggest
product
autoreact
b
cell
cast
doubt
possibl
induc
antibodi
vaccin
fourth
target
neutral
mab
loop
immunogen
also
highli
variabl
region
involv
envcoreceptor
bind
antibodi
loop
mab
mostli
effect
neutral
sensit
virus
gener
limit
breadth
reactiv
almost
exclus
specif
clade
b
virus
reflect
proven
clade
binfect
individu
cluster
human
mab
rais
b
cell
deriv
nonb
cladeinfect
individu
show
variabl
neutral
activ
two
ag
two
c
clade
primari
isol
although
particularli
neutral
sensit
final
site
describ
neutral
epitop
primarili
isol
limit
access
isol
recent
isol
partial
character
two
relat
mab
clade
ainfect
donor
appear
broad
potent
neutral
profil
report
mab
recogn
discontinu
epitop
express
nativ
env
trimer
made
segment
loop
public
first
provid
new
broadli
neutral
reagent
nonclad
b
donor
provid
proofofprincipl
new
neutral
specif
remain
discov
env
sinc
number
exist
neutral
mab
rel
broad
neutral
profil
limit
describ
date
except
walker
et
al
mab
isol
clade
b
virusinfect
donor
undertook
task
isol
new
human
mab
donor
primari
aim
isol
novel
mab
crossclad
neutral
activ
nonb
clade
donor
ii
analyz
memori
b
cell
repertoir
repres
panel
predominantli
nonb
cladeinfect
individu
use
improv
memori
b
cell
immort
method
combin
highthroughput
parallel
screen
panel
recombin
envbas
antigen
isol
panel
human
mab
character
regard
epitop
specif
breadth
neutral
fulli
character
three
mab
panel
demonstr
complementari
rel
broad
crossclad
neutral
profil
target
crown
heptad
repeat
studi
approv
ethic
committe
institut
tropic
medicin
queen
mari
univers
particip
gave
written
inform
consent
tzmbl
cell
obtain
nih
aid
research
refer
reagent
program
arrrp
cell
obtain
atcc
mab
obtain
polymun
scientif
gmbh
austria
part
collabor
aid
vaccin
discoveri
program
clade
b
c
refer
panel
env
clone
clone
obtain
niharrrp
nonclad
b
isol
provid
comprehens
antibodi
vaccin
immun
monitor
consortium
cavimc
subtyp
b
clone
jrfl
provid
denni
burton
scripp
institut
la
jolla
us
pseudovirus
produc
cotransfect
cell
envexpress
plasmid
complement
viralgenom
report
gene
vector
kindli
provid
john
r
mascola
vrc
niaid
nih
us
recombin
isol
provid
simon
jeff
imperi
colleg
london
uk
recombin
isol
bal
obtain
niharrrp
isol
mn
lai
purchas
prospectani
technogen
ltd
israel
recombin
two
mutant
provid
john
r
mascola
richard
wyatt
vrc
niaid
nih
us
recombin
solubl
recombin
iiib
obtain
cfar
nibsc
uk
recombin
ectodomain
isol
amino
acid
purchas
vybion
inc
us
modifi
version
expos
residu
hllqltvwgikqlqarilav
produc
describ
compris
includ
fusion
peptid
compris
residu
includ
cysloop
region
mper
flank
two
coil
coil
region
patient
select
inclus
studi
basi
clade
infect
viru
predominantli
nonb
clade
abil
plasma
neutral
panel
primari
isol
use
two
differer
assay
institut
tropic
medicin
panel
primari
strain
vi
primari
c
strain
primari
strain
use
select
patient
neutral
measur
dilut
plasma
plasma
dilut
mix
viru
hour
absorb
stimul
freshli
isol
pbmc
hour
virusantibodi
mixtur
remov
extens
wash
elisa
perform
day
cultur
determin
neutral
queen
mari
univers
london
tzmblbase
recombin
pseudoviru
assay
employ
select
panel
tier
clade
b
c
ae
f
bf
virus
measur
neutral
dilut
mab
isol
use
previous
describ
improv
ebv
immort
method
cultur
supernat
harvest
day
immort
assay
parallel
bind
trimer
protein
clade
clade
monomer
iiib
clade
b
recombin
ectodomain
clade
b
posit
subclon
grown
larg
scale
supernat
purif
puriti
mab
prepar
assess
use
chromogen
lal
endotoxin
assay
genscript
endotoxin
level
alway
euml
standard
elisa
use
determin
bind
mab
panel
env
briefli
elisa
plate
coat
env
antigen
block
fc
pb
incub
human
mab
wash
bound
mab
detect
incub
apconjug
goat
antihuman
igg
southern
biotech
plate
wash
substrat
pnpp
sigma
ad
plate
read
nm
rel
affin
mab
bind
respect
coat
antigen
determin
elisa
measur
concentr
mab
requir
achiev
maxim
bind
satur
abil
mab
inhibit
bind
evalu
elisa
serial
dilut
mab
preincub
ad
plate
precoat
h
plate
wash
incub
sheep
polyclon
antibodi
aalto
bioreag
follow
wash
incub
apconjug
rabbit
antisheep
igg
antibodi
abcam
cambridg
uk
extens
wash
detect
mab
purifi
protein
g
column
ge
healthcar
biotinyl
use
ezlink
nhspeo
solid
phase
biotinyl
kit
pierc
competit
unlabel
biotinyl
mab
bind
immobil
env
antigen
measur
elisa
briefli
unlabel
competitor
mab
ad
differ
concentr
h
biotinyl
mab
ad
concentr
correspond
maxim
od
level
incub
h
plate
wash
bound
biotinyl
mab
detect
use
aplabel
streptavidin
jackson
immunoresearch
percentag
inhibit
test
triplic
calcul
follow
odsampleodneg
ctr
odpo
ctr
odneg
ctr
overlap
linear
cycliz
peptid
base
overlap
peptid
strain
synthes
polypropylen
support
minicard
test
reactiv
mab
describ
pepscan
peptid
bind
analysi
carri
elisabas
format
color
substrat
quantifi
chargecoupl
devic
ccd
camera
imag
process
system
valu
mostli
rang
log
scale
similar
standard
plate
elisaread
singlecycl
infect
assay
use
measur
neutral
luciferaseencod
virion
pseudotyp
desir
env
protein
previous
describ
briefli
appropri
dilut
virioncontain
cultur
supernat
preincub
h
mab
variou
concentr
virusmab
mixtur
ad
cell
incub
day
similar
protocol
use
supernat
screen
use
tzmbl
cell
cell
lyse
britelit
reagent
perkinelm
rel
light
unit
cell
lysat
determin
luminomet
micropl
reader
verita
turner
biosystem
inhibitori
dose
defin
sampl
concentr
rel
luminesc
unit
reduc
compar
viru
control
well
neutral
data
refer
mab
taken
previou
analys
carri
ident
standard
condit
use
new
mab
report
multicycl
viru
replic
assay
use
measur
neutral
replic
compet
luciferaseencod
virus
cell
cell
line
genet
engin
clone
express
multipl
siv
entri
receptor
neutral
assay
tissu
cultur
infecti
dose
viru
incub
multipl
dilut
test
sampl
triplic
hr
total
volum
flatbottom
cultur
plate
suspens
cell
cellsml
growth
medium
contain
deae
dextranml
ad
well
plate
incub
approxim
cell
viru
control
well
posit
gfp
express
fluoresc
microscopi
approxim
day
time
cell
suspens
transfer
white
solid
plate
costar
measur
luminesc
use
britelit
luminesc
report
gene
assay
system
perkinelm
life
scienc
plasma
sampl
obtain
patient
enter
antwerp
london
cohort
infect
varieti
clade
patient
select
mab
prepar
basi
clade
infect
viru
predominantli
nonb
clade
abil
plasma
neutral
dilut
member
select
panel
tier
clade
b
c
ae
f
bf
virus
pbmcbase
infecti
primari
isol
viru
assay
tzmblbase
recombin
pseudoviru
assay
case
restrict
plasma
neutral
analysi
possibl
due
limit
amount
patient
plasma
twelv
nine
infect
donor
london
antwerp
cohort
respect
select
b
cell
immort
summar
clinic
virolog
data
includ
clade
viremia
cell
count
therapi
breadth
neutral
shown
tabl
igg
memori
b
cell
isol
select
donor
immort
ebv
presenc
cpg
describ
immort
effici
memori
b
cell
patient
significantli
lower
donor
versu
n
p
find
may
explain
recent
report
hivspecif
b
cell
present
within
popul
exhaust
memori
b
cell
character
express
inhibitori
receptor
low
level
maxim
detect
antibodi
recogn
conserv
featur
cell
cultur
supernat
screen
parallel
highthroughput
elisa
use
five
recombin
env
protein
includ
trimer
monomer
recombin
ectodomain
donor
interrog
select
b
cell
clone
produc
mab
bound
least
one
screen
antigen
mab
purifi
character
bind
specif
neutral
activ
use
extend
panel
recombin
env
protein
pseudovirus
repres
sever
clade
divers
coreceptor
usag
geograph
origin
conform
bind
data
mab
display
figur
express
halfmaxim
bind
concentr
equilibrium
approxim
equilibrium
dissoci
constant
mab
bound
sever
mab
show
broad
pattern
reactiv
recombin
protein
although
usual
within
broad
rang
valu
overal
relationship
donor
clade
clade
specif
isol
mab
neutral
activ
mab
initi
measur
use
pseudotyp
primari
isol
env
character
differ
sensit
neutral
mab
test
fix
concentr
luciferasebas
neutral
assay
use
target
cell
mab
test
whole
viru
panel
show
neutral
activ
least
one
isol
figur
three
mab
stood
breadth
neutral
activ
neutral
pseudovirus
respect
figur
mab
character
assay
potenc
figur
show
high
neutral
activ
less
potent
addit
antibodi
preferenti
neutral
isol
preferenti
neutral
isol
figur
sinc
report
neutral
target
cell
typesensit
next
use
tzmbl
target
cell
titrat
mab
larger
panel
n
predominantli
pseudovirus
tabl
gener
result
obtain
extend
panel
confirm
previou
result
show
sever
mab
potent
neutral
activ
valu
ngml
strike
except
neutral
pseudovirus
hosbas
assay
pseudovirus
tzmbl
base
assay
establish
breadth
neutral
three
novel
mab
compar
tzmbl
assay
five
mab
current
consid
broadli
reactiv
name
use
larg
multiclad
panel
compris
isol
includ
clade
b
earlytransmit
virus
three
new
mab
show
pattern
clearli
distinct
previous
describ
mab
figur
particular
neutral
high
potenc
virus
clade
b
c
virus
contrast
neutral
virus
neutral
virus
thu
compar
term
percentag
isol
neutral
superior
previous
report
show
extrem
broad
pattern
reactiv
taken
togeth
result
indic
novel
neutral
mab
isol
memori
b
cell
nonclad
b
individu
display
rel
broad
neutral
activ
sinc
one
primari
aim
isol
character
novel
mab
unusu
broad
potent
neutral
activ
focus
attent
mab
deriv
donor
infect
clade
c
uniqu
neutral
profil
potent
select
neutral
multipl
pseudovirus
figur
figur
compar
mab
bind
show
similar
bind
curv
figur
inhibit
compar
extent
bind
solidphas
figur
valu
respect
howev
crosscompetit
analysi
bind
reveal
incomplet
heterolog
inhibit
plateau
valu
approxim
figur
result
suggest
recogn
relat
nonoverlap
epitop
character
specif
measur
bind
two
mutant
mutant
bound
mab
mutant
recogn
mab
alreadi
report
bound
mutant
fail
recogn
mutant
contrast
bound
mutant
inde
bound
better
mutant
compar
wildtyp
molecul
figur
attempt
map
epitop
pepscan
analysi
use
overlap
linear
peptid
unsuccess
shown
consist
recognit
discontinu
epitop
neutral
pseudovirus
respect
figur
interestingli
isol
neutral
neutral
reciproc
isol
neutral
neutral
anoth
interest
find
discrimin
clade
much
eg
rare
neutral
clade
isol
rare
neutral
clade
c
isol
tabl
result
reveal
larg
nonoverlap
pattern
reactiv
suggest
combin
two
mab
could
effect
domin
fraction
isol
ie
taken
togeth
result
consist
recognit
surfac
proxim
domain
within
epitop
complet
distinct
recogn
mab
isol
donor
infect
clade
neutral
pseudovirus
hosbas
assay
pseudovirus
tzmblbase
assay
note
neutral
isol
test
neutral
across
clade
b
c
recombin
ag
bc
use
pepscan
analysi
linear
cyclic
peptid
librari
epitop
recogn
map
sequenc
rrsvrigpgqtf
crown
figur
similarli
epitop
addit
mab
map
region
use
differ
peptid
librari
gener
sequenc
isol
mab
mostli
reactiv
figur
minim
sequenc
recogn
mab
rang
amino
acid
singl
except
compris
g
pgrqk
sequenc
model
interact
viral
entri
process
howev
contrast
neutral
high
potenc
isol
test
mab
neutral
isol
figur
figur
similar
activ
recent
character
loopspecif
mab
deriv
nonb
clade
infect
individu
confirm
neutral
activ
cellbas
assay
challeng
replicationcompet
virus
carri
luc
report
observ
clade
b
virus
neutral
tabl
better
character
epitop
recogn
perform
replac
scan
posit
complementari
amino
acid
analysi
reveal
posit
rrsvrigpgqtf
amino
acid
substitut
abrog
bind
remark
one
mutat
found
viral
isol
posit
affect
bind
figur
howev
observ
sever
isol
neutral
encod
amino
acid
sequenc
share
isol
neutral
figur
instanc
epitop
rksvrigpgqtf
strongli
neutral
ie
share
isol
neutral
impli
epitop
unavail
antibodi
recognit
assembl
trimer
nonneutr
isol
taken
togeth
result
indic
unusu
potenc
breadth
monoclon
antibodi
note
appear
broader
reactiv
sinc
neutral
isol
isol
neutral
isol
figur
tabl
anoth
mab
unusu
breadth
activ
compar
appear
somewhat
broader
neutral
clade
c
clade
pseudovirus
comparison
difficult
differ
virus
assay
use
determin
neutral
breadth
potenc
initi
character
mab
broad
neutral
activ
hosbas
assay
lack
robust
activ
tzmbl
assay
map
epitop
test
overlap
peptid
extracellular
region
bound
peptid
qqhllqltvwgikql
overlap
hydrophob
pocket
sequenc
figur
specif
confirm
immunoprecipit
bundl
construct
trimer
construct
includ
fusion
peptid
indic
fusion
peptid
interfer
bind
figur
elisa
bound
construct
valu
ngml
respect
also
ectodomain
although
lower
avid
figur
find
may
due
partial
unfold
solid
phasebound
taken
togeth
result
indic
recogn
highli
conserv
site
within
region
sinc
occupi
restrict
surfac
transient
expos
entri
process
hypothes
access
target
epitop
might
limit
size
igg
molecul
therefor
compar
intact
igg
fab
fragment
capac
neutral
panel
pseudovirus
hosbas
assay
fab
fragment
show
markedli
increas
breadth
potenc
compar
igg
abl
neutral
isol
valu
rang
figur
tabl
contrast
igg
neutral
isol
valu
rang
addit
fab
fragment
test
tzmbl
assay
neutral
isol
valu
rang
tabl
thu
suggest
lack
activ
observ
igg
possibl
associ
differ
suscept
cell
line
type
entri
inhibitor
overal
find
suggest
reduc
size
fab
molecul
allow
increas
access
region
impli
access
larg
depend
target
cell
use
similar
concept
enhanc
neutral
profil
fab
scfv
specif
surfac
studi
use
cell
challeng
replicationcompet
virus
carri
luc
report
show
exhibit
broad
neutral
consist
result
ho
cell
assay
unlik
tzmbl
assay
abl
neutral
virus
test
tabl
epitop
recogn
remain
mab
map
use
three
experiment
approach
crosscompetit
mab
known
specif
solubl
ii
bind
mutant
construct
repres
differ
conform
intermedi
iii
pepscan
analysi
result
analysi
perform
mab
present
tabl
tabl
data
summar
pie
chart
figur
thirtyseven
mab
bound
target
primarili
loop
lesser
extent
site
tabl
first
group
mab
assign
loop
base
crosscompetit
two
loop
specif
mab
group
compris
mab
alreadi
map
loop
use
pepscan
analysi
approach
addit
mab
analyz
peptid
scan
ie
four
mab
react
wt
mutant
fail
bind
mutant
therefor
assign
cluster
notabl
one
mab
map
pepscan
analysi
novel
epitop
loop
tvyalfyrldivp
neutral
isol
tabl
fifteen
mab
assign
tent
conclus
base
capac
inhibit
bind
mab
compet
mab
case
assay
could
perform
due
lack
epitop
express
protein
use
furthermor
group
mab
show
variabl
reactiv
mutant
bind
mutant
similar
other
includ
bound
mutant
avidli
addit
new
mab
also
show
decreas
bind
mutant
suggest
may
span
broader
yet
undescrib
region
includ
element
site
final
mab
analys
provid
relev
inform
twentyon
mab
bound
target
primarili
immunodomin
cc
region
region
recogn
mab
tabl
mab
assign
cc
loop
sinc
compet
react
construct
recogn
synthet
peptid
within
region
mab
provision
assign
cc
region
sinc
compet
data
consist
immunodomin
cc
region
notion
antibodi
respons
region
overlap
epitop
sever
mab
compet
bound
construct
suggest
may
bind
fusion
peptid
region
provision
assign
region
accord
competit
bind
construct
mab
bound
specif
construct
compet
mab
test
thu
indic
complet
coil
coil
region
expos
harbor
antibodi
epitop
avail
b
cell
recognit
prehairpin
conform
concomit
bind
recombin
suggest
latter
may
partial
resembl
prefus
state
note
three
bind
mab
neither
compet
mab
test
bound
construct
repres
prehairpin
conform
nativ
figur
indic
recogn
yet
uncharacter
region
avail
recombin
protein
interestingli
mab
assign
pepscan
analysi
epitop
ctermin
region
tnliytlieesqn
proxim
epitop
neutral
isol
tabl
mab
compet
bind
spite
distinct
cognat
specif
respect
find
would
consist
proxim
sixhelix
bundl
structur
final
although
protein
use
primari
screen
includ
epitop
mper
specif
mab
isol
reinforc
idea
portion
poorli
immunogen
human
conclus
regardless
limit
breadth
neutral
extend
panel
human
mab
may
repres
use
tool
understand
molecular
basi
env
recognit
human
use
improv
ebv
immort
method
combin
broad
screen
strategi
isol
memori
b
cell
infect
donor
mab
cover
extens
antigen
surfac
env
neutral
least
one
isol
test
mab
particular
bound
crown
show
consider
neutral
breadth
panel
pseudovirus
differ
clade
span
isol
sever
studi
question
exist
individu
broadli
neutral
antibodi
specif
part
normal
immun
respons
infect
respect
isol
phage
librari
although
isol
memori
b
cell
appear
counterpart
human
sera
recent
studi
nussenzweig
cowork
use
trimer
isol
antigenbind
memori
b
cell
antibodi
sequenc
retriev
singlecel
pcr
surprisingli
although
b
cell
donor
broadli
neutral
serum
activ
none
mab
isol
properti
rais
possibl
broad
serum
neutral
activ
result
multipl
clonal
respons
uniqu
epitop
specif
restrict
breadth
viral
strain
recognit
howev
altern
interpret
might
sinc
avail
recombin
trimer
antigen
vari
structur
bait
use
b
cell
isol
optim
enrich
secret
neutral
antibodi
result
indic
monoclon
antibodi
limit
spectrum
neutral
activ
easili
isol
broad
pattern
crossclad
reactiv
rare
line
studi
walker
et
al
consist
infer
serum
neutral
specif
map
analys
respect
studi
demonstr
feasibl
ebv
immort
method
limit
size
blood
sampl
obtain
ml
peripher
blood
character
specif
neutral
activ
new
panel
human
mab
reveal
interest
featur
human
antibodi
respons
within
popul
donor
first
mab
show
neutral
activ
indic
bind
site
avail
function
env
trimer
select
highpercentag
trimer
bind
specif
may
consequ
use
trimer
env
antigen
screen
evbb
cell
supernat
second
aspect
relat
antibodi
remark
except
neutral
interestingli
nonneutr
antibodi
bound
context
recombin
trimer
wherea
effect
neutral
mab
bound
fusion
intermedi
three
new
neutral
mab
show
interest
featur
show
breadth
neutral
activ
compar
gener
complementari
asid
current
potent
rel
broad
neutral
antibodi
avail
also
show
select
neutral
multipl
isol
make
particularli
relev
templat
vaccin
design
bind
extrem
conserv
epitop
crown
neutral
isol
test
show
broader
activ
wellcharacter
mab
panel
pseudovirus
prefer
isol
characterist
mab
consist
idea
loop
display
vari
degre
context
nativ
trimer
env
protein
individu
isol
recent
observ
broaden
neutral
mab
result
obtain
particularli
intrigu
sinc
mab
broad
pattern
neutral
observ
ho
tzmbl
target
cell
mab
recogn
highli
conserv
epitop
trimer
effect
fab
fragment
compar
intact
igg
fact
may
explain
limit
access
epitop
like
expos
transient
cell
surfac
viral
entri
process
intriguingli
recent
studi
indic
tzmbl
cell
pseudovirus
penetr
cytoplasm
within
endosom
rather
cell
surfac
find
might
help
explain
lack
activ
tzmbl
assay
bind
mab
affect
endosom
environ
studi
primari
cell
requir
address
rel
import
two
entri
pathway
establish
whether
may
capabl
exert
broad
potent
neutral
activ
vivo
preliminari
studi
use
cell
challeng
replicationcompet
virus
carri
luc
report
show
exhibit
reason
broad
neutral
consist
result
ho
cell
assay
similar
fab
tzmbl
cell
assay
wherea
tzmbl
assay
sensit
certain
antibodi
mab
mab
epitop
less
sensit
neutral
assay
perhap
owe
unnatur
high
level
express
tzmbl
cell
respect
low
coreceptor
express
level
associ
delay
fusion
kinet
henc
enhanc
viru
sensit
bind
inhibitor
therefor
despit
advantag
high
throughput
tzmbl
assay
altern
neutral
assay
might
closer
relev
vivo
situat
conclus
shown
individu
high
proport
hivspecif
b
cell
produc
neutral
antibodi
possess
neutral
activ
rel
broad
neutral
coverag
short
term
reagent
test
abil
singli
combin
prevent
siv
transmiss
macaqu
challeng
model
done
previous
mab
longer
term
combin
atomiclevel
analysi
epitop
specif
mab
may
facilit
templatebas
design
immunogen
develop
vaccin
abl
induc
neutral
antibodi
wide
rang
strain
present
global
pandem
